Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021
M2 - Mon Dec 15, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/267psb/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.) to reach $19.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alere Inc - Bio Rad Laboratories Inc - Cepheid - Hologic GenProbe Inc - Hologic Inc - Illumina Inc - Immucor Inc - Life Technologies Corp - PerkinElmer Inc - Promega Corp For more information visit http://www.researchandmarkets.com/research/267psb/medical Source: Plunkett Research Ltd
CPHD: 53.39 (+0.51), ILMN: 186.22 (+2.72), ALR: 37.48 (+0.37), PKI: 43.99 (-0.06), HOLX: 26.89 (+0.10)
Alere (ALR) Downgraded From Buy to Hold
at The Street - Sun Dec 14, 7:50AM CST
Alere (ALR) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
ALR: 37.48 (+0.37)
Alere's HIV Combo Test Gets CLIA Waiver from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:20AM CST
Shares of Alere Inc. (ALR) rose 1.1% in the trading session after the news on Tuesday but pulled back to close the day lower at $37.86.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), ALR: 37.48 (+0.37), OSUR: 10.26 (+0.25)
Alere to pay USD3.00 per preferred share dividend
M2 - Thu Dec 11, 6:26AM CST
Diagnostics company Alere (NYSE:ALR) on Wednesday declared a dividend of USD3.00 per share on its Series B convertible perpetual preferred stock (NYSE:ALR.PR.
ALR: 37.48 (+0.37)
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock
PR Newswire - Wed Dec 10, 4:30PM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.
ALR: 37.48 (+0.37)
Point-Of-Care Testing Market worth $27.5 Billion by 2018 - Prominent Players in this Market - Roche Diagnostics Ltd. (Switzerland), Alere Inc. (U.S.) & Siemens AG (Germany)
M2 - Wed Dec 10, 3:42AM CST
The report "Point-Of-Care Diagnostic Market by Products (Glucose Monitoring & Infectious Diseases Testing Kits, Cardiac & Tumor Markers), by End Users (Self & Professional Monitoring), Over the Counter & Prescription Based - Global Forecast to 2018", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World.
ALR: 37.48 (+0.37)
U.S. Food and Drug Administration Grants CLIA Waiver for Alere Determine(TM) HIV-1/2 Ag/Ab Combo Test
PR Newswire - Tue Dec 09, 6:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted CLIA (Clinical Laboratory Improvement Amendments) Waiver for the Alere Determine(TM) HIV-1/2 Ag/Ab Combo test. Until now, the test has been available for sale in the United States to health facilities and laboratories licensed to conduct tests of moderate complexity. With this approval, the test will now be available for use in physician offices, clinics and other public health settings as well.
ALR: 37.48 (+0.37)
Alere Initiates Voluntary URGENT CORRECTION for Use of Alere INRatio® and INRatio®2 PT/INR Monitor System
PR Newswire - Mon Dec 08, 6:00AM CST
Alere Inc. (NYSE:ALR) has initiated a voluntary correction to inform U.S. users of the Alere INRatio® and INRatio®2 PT/INR Monitor system of certain medical conditions that should not be tested with the system (INRatio® Monitor or INRatio®2 Monitor and INRatio® Test Strips). In certain cases an INRatio® and INRatio®2 PT/INR Monitor system may provide an INR result that is clinically significantly lower than a result obtained using a reference INR system (laboratory method). This issue can arise if the patient has certain medical conditions or can occur if the instructions in the labelling for performing the test are not followed.
ALR: 37.48 (+0.37)
Global Sexually Transmitted Diseases (STDs) Testing Market 2013-2020 Disease Types, Testing Volume & Testing Devices Analysis of the $167 Billion Industry
M2 - Wed Dec 03, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/trmsj7/global_sexually) has announced the addition of the "Global Sexually Transmitted Diseases (STDs) Testing Market (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020" report to their offering. The diagnostic testing market for sexually transmitted diseases is forecast to reach $167.4 billion by 2020, registering a CAGR of 8.5% during 2014-2020 The growth in the market is chiefly attributed to the high growth in HIV and HPV testing, especially in Asia Pacificand African regions along with complimenting growth rate of the European market. Laboratory testing of STDs is significant, despite of the presence of many point-of-care (PoC) testing kits available. Some of the STDs are not diagnosed with point of care methods. For instance, HSV (Herpes Simplex Virus), low-risk HPV (Human Papilloma Virus) and Chancroid that manifest as 'warts' on the patient's skin, require physical examination by the laboratory experts. Also, many of the PoC devices are not yet approved by the regulatory health authorities such as USFDA, owing to deviations in the sensitivity and specificity criteria. For these reasons, laboratory testing is considered to be most reliable and globally accepted method for STD testing; therefore, garners a comparatively larger market share than POC testing. The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate. Key findings of the study: - Global market for diagnostic testing of STDs is gaining traction with growth in HIV and HPV screening and laboratory testing - HIV testing market segment would grow at a CAGR of 10.9% during the forecast period - Europe would be one of the lucrative markets in terms of growth. The European STDs testing market would reach $26.8 billion by 2020, with highest CAGR of 13.5% (as compared to other regional markets) - HPV testing volume and revenue will grow at much faster rate owing to higher incidences in Asia Pacific region Scope of the Report MARKET BY SEXUALLY TRANSMITTED DISEASE TYPES - Chlamydia testing - Syphilis testing - Gonorrhoea testing - Herpes Simplex Virus testing - Human Papilloma Virus testing - Human Immunodeficiency Virus testing - Chancroid testing MARKET BY LOCATION OF TESTING Laboratory Testing - Commercial/Private labs - Public Health Labs Point of Care (PoC) testing MARKET BY TESTING DEVICES Laboratory Devices: Instruments and systems - Thermal Cyclers - PCR - Lateral Flow Readers - Immunochromatographic assays - Flow Cytometers - Differential Light Scattering machines - Absorbance microplate reader - Enzyme Linked Immunosorbent Assay (ELISA) POC testing Devices: Various diagnostic kits - Phone chips (microfluidics ICT) - Portable / bench top / rapid diagnostic kits Companies Mentioned - Abbott Laboratories - Affymetrix, Inc. - Alere, Inc. - Becton Dickinson & Company - BioMerieux - Cepheid, Inc. - Danaher Corporation - DiaSorin - Hologic, Inc. - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/tr...l_sexually
ABT: 45.70 (-0.02), BDX: 139.90 (+1.44), CPHD: 53.39 (+0.51), DHR: 86.79 (-0.27), ALR: 37.48 (+0.37), HOLX: 26.89 (+0.10), AFFX: 9.80 (+0.05)
Global In Vitro Diagnostics (IVD) Market Forecasts and Opportunities, 2020 - Revenue is Expected to Reach $74.65 Billion
M2 - Wed Nov 26, 2:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/8l3wrm/global_in_vitro) has announced the addition of the "Global In Vitro Diagnostics (IVD) Market - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The IVD market revenue is expected to reach $74.65 billion by 2020, from the market value of $53.32 billion in 2013, at a CAGR of 5.34% during 2014-2020. Geographically, Asia Pacific is the fastest growing region and very opportune market that would generate highest revenue by 2020. Increase in the number of chronic and infectious diseases, and technological advancements are the major driving factors for the market. Widespread knowledge of healthcare & its benefits, and cost effectiveness are some top impacting factors of the global IVD market. The stringent regulatory policies and reimbursement issues are limiting the growth of the market. Furthermore, the rising demand for technologically advanced diagnosis devices and increased spending capabilities of consumers on health care provides huge potential for IVD in Asia Pacific market. Scope of the Report KEY MARKET SEGMENTS - Immunoassays - Clinical Chemistry - Point Of Care - Molecular Diagnostics - Hematology - Coagulation - Microbiology - Other clinical techniques MARKET BY PRODUCT TYPE - Instruments - Reagents - Data management systems - Services MARKET BY USABILITY - Disposable - Reusable MARKET BY APPLICATIONS - Infectious Diseases - Diabetes - Cancer/Oncology - Cardiology - Autoimmune Diseases - Nephrology - Drug Testing - HIV/AIDS - Others MARKET BY END USER - Hospitals - Laboratories - Academics - Point of Care Testing - Others Companies mentioned: - Abbot Laboratories - Alere Inc - Arkray Inc - Bayer AG - Becton Dickinson & Company - Biomerieux - Dahaner Corporation - Johnson & Johnson - Roche Diagnostics - Siemens - Sysmex Corp. For more information visit http://www.researchandmarkets.com/research/8l...l_in_vitro
JNJ: 104.59 (+0.31), BDX: 139.90 (+1.44), ALR: 37.48 (+0.37)
Alere elects Juliet Cunningham as VP of its Investor Relations
M2 - Mon Nov 24, 6:12AM CST
Rapid diagnostic company Alere (NYSE:ALR) announced on Friday the election of Juliet Cunningham as vice president of its Investor Relations.
ALR: 37.48 (+0.37)
The Long Case For Alere
Matthew Chan - Seeking Alpha - Fri Nov 21, 9:37AM CST
(Editors' Note: This was an entry at the Harvard/Seeking Alpha stock pitch contest on November 8, 2014). By Matthew Chan, Aaron Guo , Karan Parekh , and Julian Pei Investment Thesis Waltham, MA based Alere is a point-of-care...
ALR: 37.48 (+0.37)
Alere Appoints Juliet Cunningham to Lead Investor Relations
PR Newswire - Fri Nov 21, 7:30AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, has appointed Juliet Cunningham as Vice President, Investor Relations. In this newly created role, Cunningham will be responsible for driving communications with the investment community.
ALR: 37.48 (+0.37)
Alere to Participate in Jefferies Global Healthcare Conference
PR Newswire - Tue Nov 18, 2:34PM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, announced that it will participate in the Jefferies Global Healthcare investment conference to be held on November 19-20, 2014 at the Waldorf Hilton in London. Jon Russell, Vice President, Finance, will present at the conference on Thursday, November 20, 2014 at 8:40 am GMT.
ALR: 37.48 (+0.37)
Alere Earnings In Retrospect: Up 2.2% in the Last 20 Days (ALR)
Comtex SmarTrend(R) - Mon Nov 17, 4:18PM CST
When Alere (AMEX:ALR) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $0.52 on sales of $743.3 million. The company actually reported EPS of $0.48 on sales of $736.2 million, missing EPS estimates by $0.04 and missing revenue estimates by $7.0 million. Since the company's report, shares of Alere have risen from $39.12 to $40.00, representing a gain of 2.2% in the past 20 days.
ALR: 37.48 (+0.37)
Malaria No More Honors Alere's Contributions to Diagnosing and Eliminating Malaria in sub-Saharan Africa
PR Newswire - Fri Nov 14, 8:00AM CST
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, has been honored for its leadership in the fight against malaria with a Corporate Citizenship Award at the Malaria No More International Honors annual benefit on November 13 in New York.
ALR: 37.48 (+0.37)
Defibrillator Market to 2018 - Abbott Laboratories, Alere Inc., Ortho Clinical Diagnostics Inc. and Roche Diagnostics Analyzed
PRWeb - Thu Nov 13, 6:50AM CST
The Global Defibrillator Market 2014-2018 report says one of the major trends upcoming in the Defibrillator market is the growing use of multifunction defibrillators. The most important driver of the cardiovascular devices market is increased incidence of cardiac disorders. It is used to deliver a therapeutic dose of electrical energy in the form of electric shocks to the heart muscle for restoring normal heart rhythms.
ABT: 45.70 (-0.02), ALR: 37.48 (+0.37)
Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
PR Newswire - Wed Nov 12, 5:54AM CST
Malaria No More announced today that funding has been secured and an order has been placed for three million life-saving malaria treatments in advance of its three year, end of 2015 goal. The Power of One (Po1) campaign uses the latest social, mobile and e-commerce technologies to rally the global public in the fight against malaria. This is a major milestone for the organization and Po1 campaign partners Novartis (NYSE: NVS), the world's leading provider of malaria treatments; and Alere Inc. (NYSE: ALR), the world's leading provider of rapid diagnostic tests for infectious diseases, including malaria. To date, one million rapid diagnostic tests have been sent to Zambia through Po1.
ALR: 37.48 (+0.37), NVS: 93.91 (+0.66)
Technical Updates on Health Care Supplies Sector Stocks - Align Technology, DENTSPLY Intl., Baxano Surgical, Cerus, and Alere
PR Newswire - Wed Nov 05, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Align Technology Inc. (NASDAQ: ALGN), DENTSPLY International Inc. (NASDAQ: XRAY), Baxano Surgical Inc. (NASDAQ: BAXS), Cerus Corporation (NASDAQ: CERS), and Alere Inc. (NYSE: ALR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, November 04, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,383.84, up 0.10% and the NASDAQ Composite closed at 4,623.64, down 0.33%. The S&P 500 finished the session 0.28% lower at 2,012.10. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.72, up 0.09%, with the index gaining 10.19% in the previous three months. Register for your complimentary reports on these five stocks at:
CERS: 6.49 (+0.29), BAXS: 0.02 (unch), ALGN: 57.01 (+0.17), ALR: 37.48 (+0.37), XRAY: 53.76 (-0.24)
Upgrade Alert for Alere (ALR)
Comtex SmarTrend(R) - Thu Oct 30, 7:11AM CDT
Alere (AMEX:ALR) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $38.57 on volume of 712,000 shares, above average daily volume of 588,000. In the past 52 weeks, shares of Alere have traded between a low of $31.32 and a high of $43.00 and closed yesterday at $38.57, which is 23% above that low price. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.6%.
ALR: 37.48 (+0.37)